Download full-text PDF |
Source |
---|
Ir J Med Sci
January 2025
Sligo University Hospital, Sligo, Ireland.
Background: Chronic infection with hepatitis B virus and HIV causes significant morbidity and mortality. Effective antiviral treatment is available for both. Ireland has historically been considered a low prevalence country.
View Article and Find Full Text PDFJ Bone Miner Res
January 2025
Cancer Ecosystems Program, Garvan Institute of Medical Research, Sydney, NSW, Australia.
Rebound bone loss following denosumab discontinuation is an important barrier in the effective long-term treatment of skeletal disorders. This is driven by increased osteoclastic bone resorption following the offset of RANKL inhibition, and sequential osteoclast-directed therapy has been utilised to mitigate this. However, current sequential treatment strategies intervene following the offset of RANKL inhibition and this approach fails to consistently prevent bone loss.
View Article and Find Full Text PDFAnimal Model Exp Med
January 2025
Department of Ultrasound, First Medical Center of General Hospital of Chinese PLA, Beijing, China.
Background: This study evaluates the efficacy of gabexate mesylate thermosensitive in-situ gel (GMTI) in the treatment of beagle grade III pancreatic trauma (PT) with the assistance of contrast-enhanced ultrasound (CEUS) and investigates its mechanism of action.
Methods: A grade III PT model consisting of 15 beagle dogs with severed main pancreatic ducts was created and treated with cephalic vein injection of gabexate mesylate (GM) (1.54 mL/10 kg, TID) and peripancreatic injection of GMTI (4.
Aust Vet J
January 2025
Western Australian Veterinary Emergency and Specialty, Success, Western Australia, Australia.
This case report details an incident of hyperkalaemia that developed under general anaesthesia in a domestic cat with no prior health concerns. A 5-year-old male neutered domestic short-haired cat presented for dental extractions and subsequently developed severe bradycardia and electrocardiographic abnormalities during the procedure. Initial treatment with atropine provided limited improvement, and further investigation revealed a serum potassium concentration of 7.
View Article and Find Full Text PDFESC Heart Fail
January 2025
Department of Cardiology, Stavanger University Hospital, Stavanger, Norway.
Background: Cardiac myosin binding protein C (cMyC) is an emerging new biomarker of myocardial injury rising earlier and cleared faster than cardiac troponins. It has discriminatory power similar to high-sensitive troponins in diagnosing myocardial infarction in patients presenting with chest pain. It is also associated with outcome in patients with acute heart failure.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!